Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Glaucoma > Ab externo and ab interno XEN45 implantation show comparable IOP reduction and safety
  • Glaucoma

Ab externo and ab interno XEN45 implantation show comparable IOP reduction and safety

Ophthalmology 360

Key Takeaways

  1. Both ab externo and ab interno approaches significantly reduced IOP.
  2. Medication use declined similarly with both techniques.
  3. Ab externo implantation was associated with lower needling rates.

Both ab externo and ab interno XEN45 Gel Stent implantation techniques achieved similar reductions in intraocular pressure (IOP) and medication use, but the ab externo approach was associated with a significantly lower needling rate, according to a new systematic review and meta-analysis that compared the techniques.

Researchers conducted a comprehensive search and screened 216 articles of which 6 retrospective studies met inclusion criteria. The analysis included 614 eyes, with 318 treated using the ab externo approach and 278 treated using the ab interno technique.

Mean patient age was similar between groups, though the ab externo cohort included a higher proportion of female patients. Both approaches achieved significant reductions in IOP. The pooled standardized mean difference (SMD) for IOP reduction was -12.8 in the ab externo group and -10.1 in the ab interno group. Both techniques also resulted in significant and comparable decreases in the number of IOP-lowering medications required postoperatively, with SMDs of -2. for ab externo and -2.1for ab interno.

Needling rates were significantly lower with the ab externo approach compared to ab interno (12.1% vs 18.1%, P = 0.04). Although secondary glaucoma surgeries were more frequent in the ab interno group (19.8% vs 11.6%), the difference was not statistically significant (P = 0.28).

Reference

Hubayni R, Qedair J, Aljahdali FF, et al. Efficacy and Safety of Ab-externo Approach versus Ab-interno Approach of XEN45 Gel Stent Implantation: A Systematic Review and Meta-Analysis. Clin Ophthalmol. 2026;20:575562. doi: 10.2147/OPTH.S575562. PMID: 41773281; PMCID: PMC12949973.

Share

Related Content

  • Glaucoma

Poor sleep quality linked to glaucoma severity in older adults

  • Glaucoma

Glaucoma drainage devices provide meaningful IOP control in pediatric glaucoma

  • Glaucoma

Expanding the glaucoma treatment landscape with FLIGHT technology

  • Glaucoma

Geographic differences in glaucoma care raise concerns about equitable access

  • Glaucoma

Study finds significant IOP reductions with iDose TR and MIGS procedures

  • Glaucoma

EyeValve device lowers IOP and maintains control for 9 months in first-in-human study

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon